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Letters to the editor
into account, it is possible for hand disorders to 
develop before a clinical diagnosis of diabetes is 
made. And hand pain may offer some clinical clue to 
the diagnosis of diabetes.
Q Qiao, S Keinänen-Kiukaanniemi, U Rajala, 
A Uusimäki, S-L Kivelä
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Clinical Outcome after One Year Following Samarium-153 Particulate 
Hydroxyapatite Radiation Synovectomy
Sir,
I  was interested to read the paper, on the clinical 
effect of samarium-153 particulate hydroxyapatite 
(Sm-153 PHYP) in patients treated for persistent 
rheumatoid arthritis knee synovitis (1). Comparing 
with yttrium-90 (Y-90) colloids, the most commonly 
used radiopharmaceutical for radiation synovectomy, 
Sm-153 has a shorter half-life, respectively 2.7 and 
1.9 days, a shorter maximum penetration in the soft 
tissue respectively 10.8 and 3.1 mm and it has in 
contrast with Y-90 a y decay. The leakage of Sm-153 
using whole-body scintigraphy ranged from, 0 to 3% 
and was detected in lung, liver and regional lymph 
nodes. In our study using Y-90 for chronic knee 
synovitis, there was found a leakage of radioactivity 
48 hours after injection due to bremstrahlung meas­
ured in the inguinal nodes, the liver and the heart 
varied from 0.2 to 1.2% of the count rate measured 
above the knee joint (2). This was done with a 
collimated-thallium activated sodium iodide crystal 
( 2 x 2  inch) in the energy range of 100 to 200 KeV (3).
The clinical outcome with Y-90 silicate (5 mCi) for
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chronic synovitis of the knee joint in patients with 
rheumatoid arthritis (RA) without combining gluco- 
corticosteroid injection was after 1 year of treatment 
60% (4). In the Sm-153 PHYP treatment, combining 
with a glycocorticosteroid injection was the good 
response 44% after 1 year.
In that study (4), we found that the clinical response 
after 1 year showed no correlation with the initial 
inflammatory activity as measured by 99m-Tc- 
pertechnetate uptake measurements (5), measured just 
before treatment. On the other hand, taking the ESR 
as a measure of general disease activity, a significant 
correlation was found between the favourable outcome 
and a low ESR (measured just before treatment). 
These findings are in agreement with the observations 
and conclusion in the Sm-153 PHYP study (1), that 
patient selection for radiation synovectomy treat­
ment of persistent synovitis should favour with 
drugcontrolled or inactive synovitis of most other 
joints.
Do the authors think, that Sm-153 PHYP is a 
more suitable radiopharmaceutical than Y-90-collo- 
ids for treatment of chronic persistent knee synovitis?
In the guidelines for the individual radiopharma­
ceuticals in the different joints is recommended by 
the European Association of Nuclear Medicine
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(EANM) (6) that renium-186, with a maximum 
penetration in the soft tissue of 3.6 mm should be 
used for the treatment of the persistent chronic synov­
itis of the elbow, wrist and the ankle joint. Sm-153 
has a maximum penetration in the soft tissue of 
3.1mm and Y-90; 10.8 mm. Should Sm-153 also 
especially be used in elbow, wrist and ankle joints 
and Y-90 in the knee joints?
A. M.Th. Boerbooms 
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PHYP) may be no less efficacious than yttrium-90 
(Y-90) colloids for treating chronic synovitis of the 
knee ( 1). Comparative efficacy can only be compared 
through large randomised controlled studies.
As alluded to (1, 2), the rationale underlying 
recommendations for joint-specific application of 
radiopharmaceuticals may be flawed for a number of 
reasons: the biological (cellular) target within chronic­
ally-inflamed synovium has not been defined and thus 
its distribution within the tissue cannot be predicted: 
consistent differences between synovial dimensions in 
different appendicular joints have not been described; 
the relative effect of intra-articular distribution of 
various radiopharmaceuticals within a joint cavity 
and uptake into synovial tissue in the context o f 
radionuclide half-life, dose rate and therapeutic ß“ 
penetration and also radiopharmaceutical biological 
half-life, has never been elucidated.
We agree that Sm-153 PHYP may prove to be 
useful in therapy of elbow, wrist and ankle joints; 
however, like any other new local treatment for 
synovitis, it should be compared in large randomised, 
double-blind controlled studies with the most accept­
able, available alternative e.g. long-acting intra- 
articular glucocorticoids. Published comment reveals 
that there are few studies which examine Y-90 in this 
way (3).
Yours
G Clunie, D Lui> I Cullum, P Ell, J  Edwards
REPLY
Sir,
There are a number of theoretical reasons why 
samarium-153 particulate hydroxyapatite (Sm-153
Gavin Clunie, Metabolic Unit, Royal National Orthopaedic 
Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK.,
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